The potential of natural products to inhibit abnormal aggregation of α-Synuclein in the treatment of Parkinson's disease.
作者信息
Yang Kaixia, Lv Zhongyue, Zhao Wen, Lai Guogang, Zheng Cheng, Qi Feiteng, Zhao Cui, Hu Kaikai, Chen Xiao, Fu Fan, Li Jiayi, Xie Guomin, Wang Haifeng, Wu Xiping, Zheng Wu
机构信息
Department of Neurology, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang, China.
Neuroscience Medical Center, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, Zhejiang, China.
出版信息
Front Pharmacol. 2024 Oct 23;15:1468850. doi: 10.3389/fphar.2024.1468850. eCollection 2024.
Parkinson's disease (PD), as a refractory neurological disorder with complex etiology, currently lacks effective therapeutic agents. Natural products (NPs), derived from plants, animals, or microbes, have shown promising effects in PD models through their antioxidative and anti-inflammatory properties, as well as the enhancement of mitochondrial homeostasis and autophagy. The misfolding and deposition of α-Synuclein (α-Syn), due to abnormal overproduction and impaired clearance, being central to the death of dopamine (DA) neurons. Thus, inhibiting α-Syn misfolding and aggregation has become a critical focus in PD discovery. This review highlights NPs that can reduce α-Syn aggregation by preventing its overproduction and misfolding, emphasizing their potential as novel drugs or adjunctive therapies for PD treatment, thereby providing further insights for clinical translation.